Search
Zinc oxide
go.drugbank.com/drugs/DB09321ApprovedInvestigationalZinc oxide is an inorganic compound used in a number of manufacturing processes. … It is also widely used to treat a variety of other skin conditions, in products such as baby powder and barrier creams to treat diaper rashes, calamine cream, anti-dandruff shampoos, and antiseptic ointments
Mixtures: Calcium Mg and Zn Capsules With Vitamin D, Md Formulations Total Protector 15Categories: Compounds used in a research, industrial, or household settingDigoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigational[A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. … [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein inducersInternational brands: Digocard-GOP-145
go.drugbank.com/drugs/DB05672ExperimentalOP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.
Synonyms: (4S)-4-(((2S)-2-((2-(((2S,3S)-2-ACETAMIDO-3-METHYL-PENTANOYL)AMINO)ACETYL)AMINO)-6-AMINO-HEXANOYL)AMINO)-5-(((1S)-2-(((1S)-5-AMINO-1-(((1S)-1-(((1S,2S)-1-(((1S)-1-(((1S)-1-(((1S)-1-(((1S,2S)-1-(((1S)-5, -AMINO-1-(((1S)-1-(((1S)-1-BENZYL-2-(((1S)-1-(((1S)-1Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. ...
Mixtures: ELIQUIS 30-Day Starter Pack, ELIQUIS 30-Day Starter PackCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIt is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-oneIpilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126] … Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).
Categories: Immunoglobulin G, CTLA-4-directed Blocking AntibodyProducts: YERVOY 5 mg/ml concentrate for solution for infusion, YERVOY®5 MG /ML SOLUCION INYECTABLE PARA INFUSION INTRAVENOSAFlunarizine
go.drugbank.com/drugs/DB04841ApprovedInvestigationalFlunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesSynonyms: 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazineArmodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigationalArmodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. … (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersSynonyms: (–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide, R-modafinilUlipristal
go.drugbank.com/drugs/DB08867ApprovedInvestigationalA recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily … It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ESMYA® 5 MG COMPRIMIDOS, เอสมายาชนิดเม็ด 5 มก.Sotalol
go.drugbank.com/drugs/DB00489ApprovedInvestigationalSotalol is a methanesulfonanilide developed in 1960.[A178579] It was the first of the class III anti arrhythmic drugs.[A178579] Sotalol was first approved as an oral tablet on 30 October 1992. … [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesSynonyms: 4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide, β-cardone